Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Research advancement in immunopathogenesis of myasthenia gravis.

Literature DB >> 20101276

Research advancement in immunopathogenesis of myasthenia gravis.

Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular junction disease mediated by antibodies against the acetylcholine receptor (AChR). The etiology and immunopathogenesis of MG remain unclear. Recent research has shown the involvement of autoantibodies, lymphocytes, cytokines and chemokines, in the pathogenesis of MG. Systematic factors are also demonstrated, such as inheritance and endocrine. This review indicates the research development in immunopathogenesis of MG.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 20101276 PMCID： PMC5560374 DOI： 10.1007/s12264-010-0604-1

Source DB: PubMed Journal: Neurosci Bull ISSN： 1995-8218 Impact factor: 5.203

25 in total

Review 1. Titin and ryanodine receptor antibodies in myasthenia gravis.

Authors: G O Skeie; J A Aarli; N E Gilhus
Journal: Acta Neurol Scand Suppl Date: 2006

Review 2. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.

Authors: Marinos C Dalakas
Journal: Pharmacol Ther Date: 2006-04-27 Impact factor: 12.310

Review 3. Th17 cell induction and immune regulatory effects.

Authors: Yujing Bi; Guangwei Liu; Ruifu Yang
Journal: J Cell Physiol Date: 2007-05 Impact factor: 6.384

4. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO.

Authors: Qing-fei Kong; Bo Sun; Guang-you Wang; Dong-xu Zhai; Li-li Mu; Dan-dan Wang; Jing-hua Wang; Rui Li; Hu-lun Li
Journal: Eur J Immunol Date: 2009-03 Impact factor: 5.532

5. Interleukine-6 (IL-6) may be a link between myasthenia gravis and myoepithelioma of the parotid gland.

Authors: Pierpaolo Sassano; Francesco Paparo; Valerio Ramieri; Walter Colangeli; Giuseppe Verdino
Journal: Med Hypotheses Date: 2006-09-25 Impact factor: 1.538

6. Differential estrogen receptor expression in autoimmune myasthenia gravis.

Authors: Patrice Nancy; Sonia Berrih-Aknin
Journal: Endocrinology Date: 2005-01-20 Impact factor: 4.736

7. Interleukin-10 promoter polymorphisms in myasthenia gravis.

Authors: Espen Homleid Alseth; Hanne Linda Nakkestad; Jan Aarseth; Nils Erik Gilhus; Geir Olve Skeie
Journal: J Neuroimmunol Date: 2009-03-18 Impact factor: 3.478

Review 8. Th17 and allergy.

Authors: Keisuke Oboki; Tatsukuni Ohno; Hirohisa Saito; Susumu Nakae
Journal: Allergol Int Date: 2008-06 Impact factor: 5.836

9. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis.

Authors: Amel Meraouna; Geraldine Cizeron-Clairac; Rozen Le Panse; Jacky Bismuth; Frederique Truffault; Chantal Tallaksen; Sonia Berrih-Aknin
Journal: Blood Date: 2006-03-16 Impact factor: 22.113

10. Genetically determined neuromuscular disorders of some Roma families living in Hungary.

Authors: Laszlo Aranka; Mayer Peter; Kobor Jeno; Racz Katalin; Talosi Gyula; Endreffy Emoke; Herczegfalvi Agnes; Hortobagyi Tibor; Tiszlavicz Laszlo; Bereg Edit; Katona Marta; Szabo Janos; Karcagi Veronika
Journal: Ideggyogy Sz Date: 2009-01-30 Impact factor: 0.427

1 in total

1. MALDI-TOF-MS serum protein profiling for developing diagnostic models and identifying serum markers for discogenic low back pain.

Authors: Yin-gang Zhang; Ren-qi Jiang; Tuan-Mao Guo; Shi-Xun Wu; Wei-Juan Ma
Journal: BMC Musculoskelet Disord Date: 2014-06-02 Impact factor: 2.362

1 in total